Mymetics Corp (MYMX)

[bow-tie]

Molecular combination activates immune system against cancer ...
www.bcm.edu/news/cancer/molecular-activates...
Mar 23, 2011 · A new combination molecule –MyD88/CD40 – acts as a molecular "master switch" to turn on dendritic cells (immune system cells), improving the effectiveness of tumor vaccines, said a consortium of researchers led by Baylor College of Medicine in a report that appears in The Journal of Clinical Investigation.


The MYD88 gene provides instructions for making a protein involved in signaling within immune cells. The MyD88 protein acts as an adapter, connecting proteins that receive signals from outside the cell to the proteins that relay signals inside the cell. In particular, MyD88 transfers signals from certain proteins called Toll-like receptors and interleukin-1 (IL-1) receptors, which are important for an early immune response to foreign invaders such as bacteria. In response to signals from these receptors, the MyD88 adapter protein stimulates signaling molecules that turn on a group of interacting proteins known as nuclear factor-kappa-B. Nuclear factor-kappa-B regulates the activity of multiple genes, including genes that control the body's immune responses and inflammatory reactions. It also protects cells from certain signals that would otherwise cause them to self-destruct (undergo apoptosis).
https://ghr.nlm.nih.gov/gene/MYD88#location

Mymetics: MyD88 Medicated Signaling MPLA Stimulates production IFNc by Antigens specific CD4-Tcells and TH1-SKewed Response

Immunogenicity and Protective Capacity of a Virosomal
Respiratory Syncytial Virus Vaccine Adjuvanted with
Monophosphoryl Lipid A in Mice

Tobias Kamphuis1
*, Tjarko Meijerhof1
, Toon Stegmann1,2, Julia Lederhofer1
, Jan Wilschut1
, Aalzen de
Haan1
1 Department of Medical Microbiology, Molecular Virology Section, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands,
2 Mymetics BV, Leiden, The Netherlands
Ab